You Position: Home > Paper

Glimepiride versus glibenclamide treatment of type 2 diabetes mellitus: A systematic evaluation

( views:245, downloads:61 )
Author:
No author available
Journal Title:
Chinese Journal of Diabetes
Issue:
12
DOI:
10.3969/j.issn.1006-6187.2011.12.013
Key Word:
格列美脲;格列本脲;糖尿病,2型;荟萃分析

Abstract: 目的 系统评价格列美脲与格列本脲治疗T2DM的疗效. 方法 计算机检索PubMed、万方等数据库从建库至2010年12月间的有关文献.按Cochrane系统评价的方法评价纳入研究的质量,使用Review Manager4.2软件进行荟萃分析. 结果 共纳入9个随机对照试验.结果显示:格列美脲在降低HbA c[P=0.08,加权均数差(WMD)=-0.18,95%CI(-0.39,0.02)]、FPG[P=0.06,WMD=-0.46,95%CI(-0.94,0.01)]、餐后血糖[P=0.73,WMD=-0.16,95%CI(-1.08,0.76)]、TC[P=0.22,WMD=-0.2,95%CI(-0.51,0.12)]和TG[P=0.06,WMD=-0.30,95%CI(-0.61,0.01)]方面与格列本脲无差异;在相同血糖水平下,格列美脲组Flns[P<0.05,WMD=-0.83,95%CI(-1.21,o.45)]及餐后胰岛素[P<0.05,WMD=-5.94,95%CI(-8.79,-3.10)]升高程度低于格列本脲组;低血糖发生率格列美脲组低于格列本脲组[P<0.05,RR=0.66,95%CI(0.53,0.81)];在降低BMI方面格列美脲优于格列本脲[P=0.02,WMD=-1.49,95%CI(-2.7,-0.27)]. 结论 与格列本脲相比,格列美脲在降低血糖的同时,还能改善胰岛素抵抗及减轻体重,且低血糖发生率低,是安全有效的治疗T2DM的药物.

WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn